Health ❯ Healthcare ❯ Clinical Research

Clinical Trials

Phase 3 Studies Phase 3 Trials Efficacy Studies Randomized Controlled Trials Patient Outcomes Phase 2 Trials Phase III Trials Phase II Trials Real-World Evidence REBOOT Study Lecanemab Patient Involvement Gene Therapy for AMD Comparative Effectiveness Research Efficacy of Lecanemab EINSTEIN Jr Study Statistical Analysis Prognosis Studies ASCENT-04/KEYNOTE-D19 Patient Safety Efficacy and Safety Phase I Trials Daratumumab Diversity in Research Eli Lilly Study Ruby Blood Tests FDA Approvals Diagnostic Tests Randomised Controlled Trials P2Y12 Inhibitors Patient Participation DANFLU-2 Trial Biomarkers Cardiovascular Studies Phase Ia/Ib Trials OPTIC Trial Lancet Study Findings Data Analysis Radiation Oncology Single-Arm Trials Omega-3 Fatty Acids Pediatric Oncology COVID-19 Vaccine Trials Therapeutic Innovations Semaglutide Study Pivotal Trials Mitapivat Efficacy Tramadol Effectiveness Phase III Studies DOORwaY90 Trial NuTide:701 Phase 2 Studies Mexico Diagnostic Assays Device Approval Phase 2/3 Studies Risk Assessment Early-phase Trials Cardiovascular Health Pharmacokinetics Hormone Therapy Risks Pediatric Oncology Trials REMIX-1/-2 Trials Regulatory Affairs Autoimmune Disease Trials Gene Therapy Studies Adverse Events Nausea and Vomiting Trigeminal Nerve Stimulation (TNS) Treatment Options Evidence-Based Medicine Patient Access ASH Annual Meeting Smoking Cessation Studies Sensitivity and Specificity BMC Medicine Study Drug Efficacy Select Trial Patient Care Study Findings KARDIA-2 Study Meta-Analysis Neuroimmunology Studies

EMA Panel Backs Conditional EU Approval for Rezurock in Chronic GvHD

The opinion now goes to the European Commission for a final EU decision.

FDA Grants Priority Review to Leqembi Autoinjector for Weekly At-Home Starting Dose

HIV Drug Maraviroc Emerges as Preclinical Candidate to Curb Glioblastoma Invasion

Cochrane Update Finds No Clear Benefit of Cannabis-Based Medicines for Neuropathic Pain

FDA Grants Orphan Drug Status to Cellenkos’ CK0804 for Myelofibrosis

FDA Approves Rybrevant Faspro, a 5‑Minute Subcutaneous Amivantamab for EGFR‑Mutated Lung Cancer

China Approves Sanofi’s Qfitlia for Hemophilia A Prophylaxis and Cablivi for aTTP

FDA Approves Novartis’ Itvisma for SMA Patients Ages 2 and Up

EMA Panel Backs Higher-Dose Spinraza for 5q SMA

FDA Drops Broad Black-Box Warnings on Menopause Hormone Therapy

FDA Approves Poherdy as First Interchangeable Biosimilar to Perjeta for HER2-Positive Breast Cancer

TCT 2025: Stent‑Sparing Balloons Match DES at One Year as Lower‑Cost Alternatives Rival IVL

mRNA COVID Vaccination Linked to Longer Survival With Cancer Immunotherapy, Data Presented at ESMO

FDA Approves Libtayo as First Immunotherapy for Adjuvant Treatment of High‑Risk CSCC

FDA Approves Lurbinectedin Plus Atezolizumab for First-Line Maintenance in Extensive-Stage SCLC

FDA Approves Papzimeos as First Therapy for Adult Recurrent Respiratory Papillomatosis

CPAP Therapy Reduces Cardiovascular Events in High-Risk OSA Patients but Increases Risk in Low-Risk Group

Phase 3 Trial Validates Low-Dose Olanzapine for Chemo-Induced Nausea Without Heavy Sedation

Meta-Analysis Finds Predictable Weight Rebound After Stopping Anti-Obesity Drugs

Atrial Fibrillation at Time of Mitral Edge-to-Edge Repair Doubles Risk of Death or Rehospitalization